Percutaneous Coronary Intervention to Unprotected Left Main Stem In Different Coronary Syndromes

Original title: Comparative Outcomes After Unprotected Left Main Stem Percutaneous Coronary Intervention: A National Linked Cohort Study of 5,065 Acute and Elective Cases From the BCIS Registry (British Cardiovascular Intervention Society). Reference: Sami S. Almudarra, et al. JACC Cardiovasc Interv 2014;7:717-30

Although myocardial revascularization surgery has long been the gold standard treatment for left main lesions, PCI has become a common practice these days. Yet, it has not been thoroughly described.

This study analyzed 5065 patients undergoing PCI to the unprotected left main stem (UPLMS) between 2005 and 2010, included in the prospective registry of the British Cardiovascular Intervention Society. 784 (15.5%) presented with STEMI, 2381 (47%) with NSTEACS, and 1900 (37.5%) with CSA. In addition, 76.2% of STEMI patients, 72.6% of NSTEACS and 69.8% of CSA patients received multiple vessel PCI. DES were used in 59.4%, 71.1% and 77.8%, respectively. 

IVUS and FFR were more frequently used in programmed patients with CSA. Mortality at 30 days and at 12 months was 28.3% and 37.6% respectively, in the context of STEMI, 8.9% and 19.5% respectively in the context of NSTEACS and 1.4% and 7% respectively in the context of CSA. Radial access presented lower mortality at 30 days and at 12 months in the three groups.

Mortality predictors for acute coronary syndromes were ≥80 years, cardiogenic shock, severe left ventricular dysfunction, mechanical ventilation, renal failure and femoral access. 

Conclusion

More than half of unprotected left main PCI procedures are performed in the context of acute coronary syndromes. Cardiogenic shock is frequent in STEMI and left main lesions, and has a mortality rate higher than 50% at 30 days. Radial Access was associated to a lower mortality rate.

Commentary

This analysis shows the evolution of left main PCI in the different scenarios and, as expected, shows that the combination of STEMI and cardiogenic shock increases 30 day mortality rate by 9 times, and 12 month mortality by 5. It also contributes to the already established notion that the radial access is beneficial to all groups of patients. 

Courtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation
Buenos Aires – Argentina

Carlos Fava

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Heterotopic Treatment of the Tricuspid Valve

Tricuspid regurgitation (TR) has been associated to high morbimortality, mainly due to the development of cardiac failure, peripheral edema, ascites, kidney failure and cardiohepatic...

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Courtesy of Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...